Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corporation (DVAX) delivers innovative vaccine solutions through cutting-edge immunological research and strategic commercialization. This news hub provides investors and healthcare professionals with essential updates on the biopharmaceutical leader's clinical developments, regulatory milestones, and market activities.
Track all critical DVAX updates in one place: Access press releases covering vaccine trial progress, FDA decisions, financial results, and partnership announcements. Our curated feed includes updates on HEPLISAV-B commercialization, CpG 1018 adjuvant applications, and pipeline developments across infectious disease and cancer immunotherapy programs.
Key coverage areas: Regulatory submissions for new vaccine candidates, quarterly earnings reports, manufacturing expansions, and scientific presentations. Content is rigorously verified to ensure accuracy for both professional investors and those monitoring public health advancements.
Bookmark this page for continuous access to Dynavax's official communications and analysis of strategic initiatives shaping the future of preventive healthcare. Check regularly for developments impacting vaccine accessibility and immunological innovation.
Dynavax Technologies (DVAX) announced significant board changes as part of its ongoing refreshment program. Emilio Emini, Ph.D. and Lauren Silvernail will join the Board effective February 3, 2025. Two current directors, Peggy Phillips and Julie Eastland, will step down at the 2025 Annual Meeting.
The company plans to seek stockholder approval for Board declassification at the 2025 Annual Meeting. If approved, directors will transition to one-year terms starting from the 2026 Annual Meeting, with all directors standing for annual election by 2028.
The company reported strong performance, achieving record annual revenue for HEPLISAV-B in 2024 and maintaining an active $200 million share repurchase program. Following the 2025 Annual Meeting, the Board will consist of nine directors, with six of its eight independent directors appointed since 2020.
Dynavax Technologies (DVAX) reported preliminary unaudited financial highlights for Q4 and full year 2024. HEPLISAV-B achieved record annual revenue of $268 million, representing 26% growth year-over-year, and Q4 revenue of $71 million, up 39% from Q4 2023.
The company expects the U.S. hepatitis B adult vaccine market to reach over $900 million in annual sales by 2030, with HEPLISAV-B targeting at least 60% market share. The company completed enrollment in its Phase 1/2 shingles vaccine trial, with top-line results expected in Q3 2025. Additionally, Dynavax secured a new $30 million contract with the U.S. Department of Defense for plague vaccine development.
As of December 31, 2024, the company reported approximately $714 million in cash, cash equivalents, and marketable securities.
Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has announced its upcoming participation at the 7th Annual Evercore HealthCONx Conference. The presentation is scheduled for Tuesday, December 3 at 2:35 p.m. ET.
Interested parties can access the webcast through the 'Events & Presentations' section on the company's investor relations website at investors.dynavax.com/events-presentations.
Dynavax Technologies has announced a $100 million Accelerated Share Repurchase (ASR) program under an agreement with Goldman Sachs & Co. . This ASR is part of a $200 million share repurchase program authorized by Dynavax's Board of Directors in November 2024. Upon completion, $100 million will remain in the program.
Dynavax will initially receive approximately 6.1 million shares, representing around 80% of the $100 million paid, based on the $13.01 closing stock price on November 8, 2021. The final number of shares repurchased will be determined by the volume-weighted average prices during the ASR term, with final settlement expected in Q1 2025. As of November 5, 2024, Dynavax had about 131.5 million shares outstanding.
Chief Financial Officer Kelly MacDonald stated that the ASR reflects confidence in Dynavax's business and commitment to shareholder value through strategic capital allocation.
Dynavax (DVAX) reported strong Q3 2024 financial results, with HEPLISAV-B achieving record quarterly net product revenue of $79.3 million, up 27% year-over-year. The company's total revenues reached $80.6 million, a 16% increase from Q3 2023. HEPLISAV-B's U.S. market share grew to 44%, with particularly strong performance in retail pharmacy (55%) and IDN segments (56%). The company expects the hepatitis B adult vaccine market to reach over $900 million by 2030, with HEPLISAV-B targeting at least 60% market share. Dynavax reported net income of $17.6 million and maintains a strong cash position of $764 million. The company also announced a $200 million share repurchase program and discontinued its Tdap-1018 development program.
Dynavax Technologies (Nasdaq: DVAX) has announced a new $200 million share repurchase program with no expiration date, expected to be executed within one year. The company's management will determine the timing and amount of repurchases based on business capital needs, stock price, and market conditions. The program can be implemented through various methods including open market purchases and block trades, and can be suspended at any time. CFO Kelly MacDonald emphasized this aligns with their disciplined capital allocation approach, aiming to create shareholder value while maintaining flexibility for HEPLISAV-B development, research pipeline advancement, and portfolio expansion.
Dynavax Technologies (DVAX) has implemented a -duration stockholder rights plan in response to Deep Track Capital's recent accumulation of 13.6% of company stock. The plan grants stockholders one preferred share purchase right per common share as of November 8, 2024. Rights become exercisable if any entity acquires 15% ownership (18% for passive institutional investors), allowing holders to purchase additional shares at $52.00. The plan aims to protect stockholder value and prevent control acquisition without appropriate premium. The Rights Plan will be submitted for stockholder vote at the 2025 Annual Meeting and will expire thereafter unless ratified, in which case it continues until October 28, 2025.
Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on vaccine development, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Interested parties can access the webcast through the company's investor relations website, with a replay available for 30 days. Participants are advised to register and connect 10 minutes before the call.
Dynavax Technologies (Nasdaq: DVAX) reported strong Q2 2024 financial results, highlighting record HEPLISAV-B net product revenue of $70.2 million, a 24% year-over-year increase. The company reaffirmed its full-year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million. Dynavax's total estimated market share in the U.S. increased to approximately 42%, with significant growth in retail pharmacy and IDN segments.
The company initiated dosing in a Phase 1/2 trial for its novel shingles vaccine program, with clinical data expected in 2H 2025. Dynavax also provided updates on its Tdap and plague vaccine programs. Financially, the company reported total revenues of $73.8 million, a 22% year-over-year increase, and net income of $11.4 million or $0.09 per share basic. Cash and marketable securities stood at $735.6 million as of June 30, 2024.
Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on innovative vaccines, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, after U.S. financial markets close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET/1:30 p.m. PT.
Investors can access the live audio webcast through the 'Events & Presentations' page on the company's website. A replay will be available for 30 days following the event. To participate in the call, attendees must register using the provided caller registration link. It is recommended that participants join the conference call or webcast approximately 10 minutes before the scheduled start time.
